In particular, the splicing isoforms of certain genes, such as H2AFY, TIMPI, SMURF2, and ID1, have been identified to possess inhibitory proliferation properties, indicating that therapeutic approaches targeting these variants would be highly beneficial for disease control and treatment in CRC patients. This evidence concerns the gene ID1 and colorectal carcinoma.